A comparison of bromocriptine & cabergoline on fertility outcome of
hyperprolactinemic infertile women undergoing intrauterine insemination.
Author(s): Motazedian S, Babakhani L, Fereshtehnejad SM, Mojthahedi K.
Affiliation(s): Shiraz University of Medical Sciences & Health Services, Shiraz, Iran.
Publication date & source: 2010, Indian J Med Res. , 131:670-4
BACKGROUND & OBJECTIVES: The aim of this study was to compare the effects of
bromocriptine versus cabergoline on pregnancy in hyperprolactinaemic infertile
women.
METHODS: A total of 183 infertile women with hyperprolactinemia undergoing
intrauterine insemination (IUI) were randomly divided into two groups. Group A:
94 with bromocriptine and group B:89 with cabergoline. The efficacy and safety
was evaluated on the basis of normalization of prolactin levels, normalization of
menstrual cycle, disappearance of galactorrhea, occurrence of pregnancy and
adverse effects with each of these medications.
RESULTS: The presence of galactorrhea and irregular menstruation were
significantly lower in patients of group B than group A (P<0.001 and P=0.011,
respectively) with a significant lower prevalence of side effects in cabergoline
group. Pregnancy was significantly more achieved among the women with the
treatment of cabergoline (82%) as compared to bromocriptine (56.4%) (P<0.001).
INTERPRETATION & CONCLUSION: Our results suggest that cabergoline treatment
in infertile women with prolactinemia is more effective. It lowers prolactin with
better tolerability and much more effective in the achievement of pregnancy.
|